{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:22:20Z","timestamp":1787008940055,"version":"build-2736575974"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["ABT-263"],"award-info":[{"award-number":["ABT-263"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intestinal fibrosis and subsequent intestinal obstruction are common complications of Crohn\u2019s disease (CD). Current therapeutics combat inflammation, but no pharmacological therapy exists for fibrostenotic disease. Pathological persistence of activated intestinal myofibroblasts is a key driver of fibrosis in CD. In other organ systems, BH-3 mimetic drugs that affect Bcl-2 apoptotic pathways induce apoptosis in activated myofibroblasts and reduce fibrogenic gene expression, thereby reducing fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated the proapoptotic and antifibrotic efficacy of several classes of BH-3 mimetics in 2 in vitro fibrogenesis models. The candidate molecule, ABT-263, was advanced to a 3-dimensional human intestinal organoid (HIO) model. Finally, the therapeutic efficacy of ABT-263 was evaluated in the mouse Salmonella typhimurium intestinal fibrosis model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The BH-3 mimetics induced apoptosis, repressed fibrotic protein expression, and reduced fibrogenic gene expression in normal human intestinal myofibroblasts. The BH-3 mimetics that target Bcl-2 and Bcl-xl demonstrated the greatest efficacy in vitro. The ABT-199 and ABT-263 induced apoptosis and ameliorated fibrogenesis in the in vitro myofibroblast models. In the HIO model, ABT-263 inhibited fibrogenesis and induced apoptosis. In the mouse S. typhimurium model, dose-dependent reduction in macroscopic pathology, histological inflammation, inflammatory and fibrotic gene expression, and extracellular matrix protein expression indicated ABT-263 may reduce intestinal fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In vitro, the antifibrotic efficacy of BH-3 mimetics identifies the Bcl-2 pathway as a druggable target and BH-3 mimetics as putative therapeutics. Reduction of inflammation and fibrosis in the mouse intestinal fibrosis model by ABT-263 indicates BH-3 mimetics as potential, novel antifibrotic therapeutics for Crohn\u2019s disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izab166","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T08:40:00Z","timestamp":1627116000000},"page":"161-175","source":"Crossref","is-referenced-by-count":15,"title":["Effect of ABT-263 on Intestinal Fibrosis in Human Myofibroblasts, Human Intestinal Organoids, and the Mouse\n                    <i>Salmonella typhimurium<\/i>\n                    Model"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3338-8315","authenticated-orcid":false,"given":"Laura A","family":"Johnson","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva S","family":"Rodansky","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhdao","family":"Tran","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G","family":"Collins","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A","family":"Eaton","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Malamet","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calen A","family":"Steiner","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cell and Developmental Biology, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R","family":"Spence","sequence":"additional","affiliation":[{"name":"Department of Cell and Developmental Biology, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D R","family":"Higgins","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,24]]},"reference":[{"key":"2023102622183657500_CIT0001","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ibd.20029","article-title":"Update on the incidence and prevalence of Crohn\u2019s disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000","volume":"13","author":"Loftus","year":"2007","journal-title":"Inflamm Bowel Dis."},{"key":"2023102622183657500_CIT0002","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.gastro.2016.09.047","article-title":"Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases","volume":"152","author":"Rieder","year":"2017","journal-title":"Gastroenterology."},{"key":"2023102622183657500_CIT0003","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/1751-2980.12852","article-title":"The fate of myofibroblasts during the development of fibrosis in Crohn\u2019s disease","volume":"21","author":"Li","year":"2020","journal-title":"J Dig Dis."},{"key":"2023102622183657500_CIT0004","first-page":"171","article-title":"The role of myofibroblasts in wound healing","volume":"64","author":"Hinz","year":"2016","journal-title":"Curr Res Transl Med."},{"key":"2023102622183657500_CIT0005","first-page":"43","article-title":"Mechanisms for the resolution of organ fibrosis","volume":"34","author":"Horowitz","year":"2019","journal-title":"Physiology (Bethesda)."},{"key":"2023102622183657500_CIT0006","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41584-019-0324-5","article-title":"Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases","volume":"16","author":"Hinz","year":"2020","journal-title":"Nat Rev Rheumatol."},{"key":"2023102622183657500_CIT0007","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat Rev Mol Cell Biol."},{"key":"2023102622183657500_CIT0008","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.matbio.2018.01.020","article-title":"BH3 mimetics as anti-fibrotic therapy: unleashing the mitochondrial pathway of apoptosis in myofibroblasts","volume":"68-69","author":"Kuehl","year":"2018","journal-title":"Matrix Biol."},{"key":"2023102622183657500_CIT0009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"key":"2023102622183657500_CIT0010","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/cdd.2015.50","article-title":"The BCL-2 protein family, BH3-mimetics and cancer therapy","volume":"22","author":"Delbridge","year":"2015","journal-title":"Cell Death Differ."},{"key":"2023102622183657500_CIT0011","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cbpa.2017.06.014","article-title":"Progress in targeting the BCL-2 family of proteins","volume":"39","author":"Garner","year":"2017","journal-title":"Curr Opin Chem Biol."},{"key":"2023102622183657500_CIT0012","doi-asserted-by":"crossref","first-page":"(420)","DOI":"10.1126\/scitranslmed.aal3765","article-title":"Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis","volume":"9","author":"Lagares","year":"2017","journal-title":"Sci Transl Med."},{"key":"2023102622183657500_CIT0013","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ijrobp.2017.02.216","article-title":"Inhibition of Bcl-2\/xl with ABT-263 selectively kills senescent type ii pneumocytes and reverses persistent pulmonary fibrosis induced by ionizing radiation in mice","volume":"99","author":"Pan","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2023102622183657500_CIT0014","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/hep.29464","article-title":"Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-\/-) mice","volume":"67","author":"Moncsek","year":"2018","journal-title":"Hepatology."},{"key":"2023102622183657500_CIT0015","first-page":";76(4):452\u2013460.","article-title":"The senolytic agent navitoclax inhibits angiotensin II-induced heart failure in mice Navitoclax inhibits heart failure","author":"Jia","year":"2020","journal-title":"J Cardiovasc Pharmacol."},{"key":"2023102622183657500_CIT0016","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/ibd\/izy147","article-title":"BCL2 regulates differentiation of intestinal fibroblasts","volume":"24","author":"Weder","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2023102622183657500_CIT0017","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"2023102622183657500_CIT0018","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S2152-2650(20)30467-5","article-title":"New Therapies in development for myelofibrosis","volume":"20","author":"Chifotides","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2023102622183657500_CIT0019","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med."},{"key":"2023102622183657500_CIT0020","first-page":";18(3):460\u2013471.","article-title":"Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a \u201ctop-down\u201d approach to intestinal fibrosis in mice","author":"Johnson","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"2023102622183657500_CIT0021","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.yexmp.2012.04.014","article-title":"CARD-024, a vitamin D analog, attenuates the pro-fibrotic response to substrate stiffness in colonic myofibroblasts","volume":"93","author":"Johnson","year":"2012","journal-title":"Exp Mol Pathol."},{"key":"2023102622183657500_CIT0022","first-page":";27(3):303\u2013316.","article-title":"AXL Is a potential target for the treatment of intestinal fibrosis","author":"Steiner","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2023102622183657500_CIT0023","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/MIB.0b013e3182813297","article-title":"Matrix stiffness corresponding to strictured bowel induces a fibrogenic response in human colonic fibroblasts","volume":"19","author":"Johnson","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"2023102622183657500_CIT0024","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.yexmp.2015.03.033","article-title":"Intestinal organoids: a model of intestinal fibrosis for evaluating antifibrotic drugs","volume":"98","author":"Rodansky","year":"2015","journal-title":"Exp Mol Pathol."},{"key":"2023102622183657500_CIT0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/01.MIB.0000437615.98881.31","article-title":"Novel Rho\/MRTF\/SRF inhibitors block matrix-stiffness and TGF-\u03b2-induced fibrogenesis in human colonic myofibroblasts","volume":"20","author":"Johnson","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"2023102622183657500_CIT0026","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature09691","article-title":"Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro","volume":"470","author":"Spence","year":"2011","journal-title":"Nature."},{"key":"2023102622183657500_CIT0027","first-page":"724","article-title":"Optimisation of intestinal fibrosis and survival in the mouse S. Typhimurium model for anti-fibrotic drug discovery and preclinical applications","volume":"11","author":"Johnson","year":"2017","journal-title":"J Crohns Colitis."},{"key":"2023102622183657500_CIT0028","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods."},{"key":"2023102622183657500_CIT0029","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ibd.21929","article-title":"Spironolactone and colitis: increased mortality in rodents and in humans","volume":"18","author":"Johnson","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"2023102622183657500_CIT0030","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1053\/j.gastro.2007.12.043","article-title":"Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis","volume":"134","author":"Grassl","year":"2008","journal-title":"Gastroenterology."},{"key":"2023102622183657500_CIT0031","first-page":";S0016-5085(19)41035-4.","article-title":"Challenges in the pathophysiology, diagnosis and management of intestinal fibrosis in inflammatory bowel disease","author":"D\u2019Haens","year":"2019","journal-title":"Gastroenterology."},{"key":"2023102622183657500_CIT0032","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbadis.2012.12.007","article-title":"Strategies for anti-fibrotic therapies","volume":"1832","author":"Rosenbloom","year":"2013","journal-title":"Biochim Biophys Acta."},{"key":"2023102622183657500_CIT0033","doi-asserted-by":"crossref","first-page":"101603","DOI":"10.1016\/j.bpg.2019.02.005","article-title":"What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn\u2019s disease activity?","volume":"38\u201339","author":"Ma","year":"2019","journal-title":"Best Pract Res Clin Gastroenterol."},{"key":"2023102622183657500_CIT0034","doi-asserted-by":"crossref","first-page":"C405","DOI":"10.1152\/ajpcell.00300.2017","article-title":"Gut organoids: mini-tissues in culture to study intestinal physiology and disease","volume":"317","author":"Almeqdadi","year":"2019","journal-title":"Am J Physiol Cell Physiol."},{"key":"2023102622183657500_CIT0035","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.tranon.2019.01.009","article-title":"Novel synergistic combination of mitotic arrest and promotion of apoptosis for treatment of pancreatic adenocarcinoma","volume":"12","author":"Duan","year":"2019","journal-title":"Transl Oncol."},{"key":"2023102622183657500_CIT0036","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","article-title":"Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin Cancer Res."},{"key":"2023102622183657500_CIT0037","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","article-title":"A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia","volume":"56","author":"Kipps","year":"2015","journal-title":"Leuk Lymphoma."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/2\/161\/52624532\/izab166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/2\/161\/52624532\/izab166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T18:18:59Z","timestamp":1698344339000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/28\/2\/161\/6327635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,24]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,7,24]]},"published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izab166","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,7,24]]}}}